Liver, NAFLD and COVID-19.
Horm Metab Res
; 54(8): 522-531, 2022 Aug.
Article
in English
| MEDLINE | ID: covidwho-1805722
ABSTRACT
Coronavirus disease 2019 (COVID-19) is characterized by a wide clinical spectrum that includes abnormalities in liver function indicative of liver damage. Conversely, people with liver diseases are at higher risk of severe COVID-19. In the current review, we summarize first the epidemiologic evidence describing the bidirectional relationship between COVID-19 and liver function/liver diseases. Additionally, we present the most frequent histologic findings as well as the most important direct and indirect mechanisms supporting a COVID-19 mediated liver injury. Furthermore, we focus on the most frequent liver disease in the general population, non-alcoholic or metabolic-associated fatty liver disease (NAFLD/MAFLD), and describe how COVID-19 may affect NAFLD/MAFLD development and progression and conversely how NAFLD/MAFLD may further aggravate a COVID-19 infection. Finally, we present the long-term consequences of the pandemic on the development and management of NAFLD.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Non-alcoholic Fatty Liver Disease
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Horm Metab Res
Year:
2022
Document Type:
Article
Affiliation country:
A-1834-9008
Similar
MEDLINE
...
LILACS
LIS